These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36372355)

  • 1. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
    Martin TG; Capra M; Mohty M; Suzuki K; Quach H; Cavo M; Moreau P; Dimopoulos M; Yong K; Tekle C; Foster MC; Barnes Y; Risse ML; Mikhael J
    Transplant Cell Ther; 2023 Feb; 29(2):134.e1-134.e7. PubMed ID: 36372355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
    Facon T; Moreau P; Martin TG; Spicka I; Oriol A; Koh Y; Lim A; Mikala G; Rosiñol L; Yağci M; Cavo M; Yong K; Risse ML; Asset G; Schwab S; Martinez G
    Hematol Oncol; 2022 Dec; 40(5):1020-1029. PubMed ID: 35653225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.
    Kim K; Min CK; Koh Y; Ishizawa K; Kim SH; Ito S; Tanaka J; Uchiyama M; Kawano Y; Kim JS; Moreau P; Martin T; Dong Y; Risse ML; Suzuki K
    Int J Hematol; 2022 Oct; 116(4):553-562. PubMed ID: 35578151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isatuximab plus carfilzomib and dexamethasone in patients with early
    Facon T; Moreau P; Baker R; Min CK; Leleu X; Mohty M; Karlin L; Armstrong NM; Tekle C; Schwab S; Risse ML; Martin T
    Haematologica; 2024 Feb; 109(2):604-616. PubMed ID: 37584290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
    Facon T; Moreau P; Špicka I; Suzuki K; Yong K; Mikhael J; Fukao T; Bisht K; Armstrong NM; Macé S; Risse ML; Martin T
    Hematol Oncol; 2024 Mar; 42(2):e3258. PubMed ID: 38402467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
    Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
    Martin T; Mikhael J; Hajek R; Kim K; Suzuki K; Hulin C; Garg M; Quach H; Sia H; George A; Konstantinova T; Risse ML; Asset G; Macé S; van de Velde H; Moreau P
    Blood Adv; 2022 Aug; 6(15):4506-4515. PubMed ID: 35594559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial.
    Yong K; Martin T; Dimopoulos MA; Mikhael J; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Casca F; Macé S; Risse ML; Moreau P
    Lancet Haematol; 2024 Oct; 11(10):e741-e750. PubMed ID: 39067465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.
    Capra M; Martin T; Moreau P; Baker R; Pour L; Min CK; Leleu X; Mohty M; Segura MR; Turgut M; LeBlanc R; Risse ML; Malinge L; Schwab S; Dimopoulos M
    Haematologica; 2022 Jun; 107(6):1397-1409. PubMed ID: 34647444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
    Spicka I; Moreau P; Martin TG; Facon T; Martinez G; Oriol A; Koh Y; Lim A; Mikala G; Rosiñol L; Yağci M; Cavo M; Risse ML; Asset G; Macé S; van de Velde H; Yong K
    Eur J Haematol; 2022 Nov; 109(5):504-512. PubMed ID: 35871357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.
    Kawano Y; Kim K; Min CK; Koh Y; Ishizawa K; Kim SH; Ito S; Tanaka J; Uchiyama M; Ishida T; Kim JS; Moreau P; Martin T; Tada K; Risse ML; Suzuki K
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e360-e367. PubMed ID: 37479547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
    Richter J; Lin PL; Garcia-Horton V; Guyot P; Singh E; Zhou ZY; Sievert M; Taiji R
    Cancer Med; 2023 Apr; 12(7):8005-8017. PubMed ID: 36726287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.
    Banerjee R; Lo M; Martin TG
    Future Oncol; 2021 Dec; 17(35):4849-4860. PubMed ID: 34553603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA.
    Beksac M; Spicka I; Hajek R; Bringhen S; Jelínek T; Martin T; Mikala G; Moreau P; Symeonidis A; Rawlings AM; van de Velde H; Richardson PG
    Leuk Res; 2022 Nov; 122():106948. PubMed ID: 36108425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
    Martin T; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Casca F; Macé S; Risse ML; Moreau P
    Blood Cancer J; 2023 May; 13(1):72. PubMed ID: 37156782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
    Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
    Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isatuximab: A Review of Its Use in Multiple Myeloma.
    Frampton JE
    Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
    Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
    Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design.
    Moreau P; Dimopoulos MA; Yong K; Mikhael J; Risse ML; Asset G; Martin T
    Future Oncol; 2020 Jan; 16(2):4347-4358. PubMed ID: 31833394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.